Recently, two Indian companies have come in for observations from the US Food and Drug Administration (FDA) on their non-adherence to current Good Manufacturing Practices(cGMP). Concerns over cGMP is not something that’s surfacing today, nor is it restricted to Indian companies. But it is in the interest of Indian drugmakers to be up to scratch, given their role as a global supplier of medicines and as they step up into making more specialized medicines.
Against this background, Ashishchandra Rao, Partner, Economic Laws Practice (ELP) talks to Jyothi Datta from The Hindu businessline in the latest article “Quality Quagmire. Why drugmakers are dialing C for current good manufacturing practices” about the guidelines surrounding Good Manufacturing Practices(cGMP).
To know more, explore the article here: https://bitly.ws/33sFC